Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Ocata Therapeutics Inc (NASDAQ: OCAT) acted responsibly on behalf of investors’ profitability in the planned $379 million sale to Astellas Pharma Inc (OTC: ALPMY).

On November 10, 2015, Ocata Therapeutics Inc (NASDAQ: OCAT) and Astellas Pharma Inc (OTC: ALPMY) announced that they had entered into a merger agreement. Under the terms of the merger agreement, Astellas will offer Ocata shareholders $8.50 per share in cash for all outstanding shares.    

Based in Marlborough, Massachusetts, and founded in 1994 Ocata Therapeutics Inc is a biopharmaceutical company, focusing primarily on cell therapy for ophthalmology.

The investigation focuses on whether NASDAQ: OCAT investors received the highest price and whether the directors of Ocata Therapeutics Inc acted in the best interest of Ocata Therapeutics Inc company and its shareholders.   

If you purchased Ocata Therapeutics Inc (NASDAQ: OCAT) prior to November 10, 2015, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185